key: cord-0925523-j4b88irz
authors: Okada, Masaji; Takemoto, Yuji; Okuno, Yoshinobu; Hashimoto, Satomi; Fukunaga, Yukari; Tanaka, Takao; Kita, Yoko; Kuwayama, Sechiko; Muraki, Yumiko; Kanamaru, Noriko; Takai, Hiroko; Okada, Chika; Sakaguchi, Yayoi; Furukawa, Izumi; Yamada, Kyoko; Izumiya, Miwa; Yoshida, Shigeto; Matsumoto, Makoto; Kase, Tetsuo; Peiris, J. S. M.; deMello, Daphne E.; Chen, Pei-Jer; Yamamoto, Naoki; Yoshinaka, Yoshiyuki; Nomura, Tatsuji; Ishida, Isao; Morikawa, Shigeru; Tashiro, Masato; Sakatani, Mitsunori
title: Development of Vaccines and Passive Immunotherapy Against Sars Coronavirus Using Mouse and Scid-PBL/hu Mouse Models
date: 2006
journal: The Nidoviruses
DOI: 10.1007/978-0-387-33012-9_102
sha: 978d74fe934b85559f21f8de5b5784424aec0b06
doc_id: 925523
cord_uid: j4b88irz

We have investigated novel vaccines strategies against severe acute respiratory syndrome (SARS) CoV infection using cDNA constructs encoding the structural antigens; spike (S), membrane (M), envelope (E), or nucleocapsid (N) protein, derived from SARS CoV (strain HKU39849, TW1, or FFM-1). As SARS-CoV is thought to infect the alveolar epithelial cell of the lung,in the present study, a type II alveolar epithelial cell clone, T7, was used to analyze the mechanism of CTL against SARS CoV membrane antigens. Mice vaccinated with SARS CoV (N) DNA or (M) DNA using pcDNA 3.1 (+) plasmid vector showed T-cell immune responses (CTL induction and proliferation) against type II alveolar epithelial cells (T7) transfected with SARS (N) or (M) DNA, respectively. To determine whether these DNA vaccines could induce T-cell immune responses in humans as well as in mice, SCID-PBL/hu mice were immunized with these DNA vaccines. PBL from healthy human volunteers were administered i.p. into IL-2 receptor gamma-chain-disrupted NOD-SCID mice [IL-2R(-/-) NOD-SCID]. SCID-PBL/hu mice thus constructed can be used to analyze the human immune response in vivo. The SCID-PBL/hu mice were immunized with SARS (N) DNA or (M) DNA and analyzed for a human T-cell immune response. The M DNA vaccine enhanced CTL activity and proliferation in the presence of M peptide in SCID-PBL/hu mice. Furthermore, the SARS N DNA vaccine induced CTL activity (IFN-gamma production by recombinant N protein or N protein-pulsed autologous B blast cells) and proliferation of spleen cells in SCID-PBL/hu mice. These results, demonstrate that SARS M and N DNA vaccines induced human CTL and human T-cell proliferative responses. On the other hand, we have developed SARS DNA vaccines that induce human neutralizing antibodies and human monoclonal antibodies against SARS CoV. Transgenic mice expressing SARS-CoV receptor (angiotensin converting enzyme 2) are also under development. These vaccines are expected to induce immune responses specific for SARS CoV in human and should provide useful tool for development of protective vaccines.

We have investigated novel vaccines strategies against severe acute respiratory syndrome (SARS) CoV infection using cDNA constructs encoding the structural antigens; spike (S), membrane (M), envelope (E), or nucleocapsid (N) protein, derived from SARS CoV (strain HKU39849, TW1, or FFM-1). As SARS-CoV is thought to infect the alveolar epithelial cell of the lung,in the present study, a type II alveolar epithelial cell clone, T7, was used to analyze the mechanism of CTL against SARS CoV membrane antigens. Mice On the other hand, we have developed SARS DNA vaccines that induce human neutralizing antibodies and human monoclonal antibodies against SARS CoV. Transgenic mice expressing SARS-CoV receptor (angiotensin converting enzyme 2) are also under development. These vaccines are expected to induce immune responses specific for SARS CoV in human and should provide useful tool for development of protective vaccines.

The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of corona virus, SARS corona virus (SARS-CoV) more than 8400 patients in about 7 months in over 30 countries and caused more than 800 deaths. The deadly epidemic has had significant impacts on many health, social, economic and political aspects. SARS may resurge in the near future. However, no SARS vaccine is currently available for clinical use. Therefore, we have developed novel vaccine candidates against SARS CoV using cDNA constructs encoding the structural antigens; S, M, E, or N protein. In immunized mice, neutralizing antibodies against the virus and T-cell immunity against virus-infected-cells were studied, since these responses play important roles in protection against many virus infections. In particular, CD8 + CTL plays an important role in T cell immunity against virus infections and in the eradication of murine and human cancers. 4, 5 In the present study, a type II alveolar epithelial cell clone, T7, was used for activity (IFN-γ production by recombinant N protein or N protein-pulsed autologous B γ 1,2,3 . SARS has infected 

analyzing precise mechanism of CTL against SARS-CoV membrane antigens, as the SARS-CoV infects alveolar epithelial cell in the lungs. 6 Furthermore, the SCID-PBL/hu model, which is capable of analyzing in vivo human immune response, was also used because it is a more relevant translational model for human cases. 4 These vaccines induce human immune responses (neutralizing antibody and CTL) specific for SARS CoV in human and should provide useful tool for development of protective vaccines.

Three SARS CoV strains HKU39849 1 , TW-1, and FFM-1 2 and their cDNAs were used. S, M, N, or E cDNA was transferred into pcDNA 3.1(+) vector and pcDNA 3.1(+)/vs-His Topo (QIAGEN K K, Tokyo, Japan). These genes were expressed in eukaryotic cells and Escherichia coli. pcDAN 3.1(+) vector, 50 μg each, containing SARS S, M, N, or E DNA was injected i.m. (M. tibia anterior) into C57BL/6 mice (female, 8 weeks, CLEA Japan Inc, Japan) and BALB/c mice (female, 8 weeks) three times, at an interval of 7 days. Neutralizing antibodies against SARS CoV in the serum from the mice immunized with SARS S, M, N, or E DNA vaccines were assayed using Vero-E6 cell. CTL activity against SARS-CoV was studied using human type II alveolar epithelial cells, T7, expressing SARS antigens. 6 PBL from healthy human volunteers were administered i.p. SCID-PBL/hu mice were constructed. 4 SARS DNA vaccines at 50 μg were injected i.m. into the SCID-PBL/hu mice. CTL activity of human CD8-positive lymphocytes in the spleen from SCID-PBL/hu was assessed using IFN-γ production and 51 Cr-release assay 4, 5 Human monoclonal antibodies were produced from B cell hybridoma using P3U1 myeloma cell and spleen cells from human immunoglobulin transchromosomic mice (KM mice). while another SARS DNA vaccine encoding N protein generated IFN-γ-producing

This study was supported by Grant-in-Aid for science and technology and Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, and Labour Science Research Grant from the Ministry of Health, Labour, and Welfare

It has been demonstrated that angiotensin-converting enzyme 2 (ACE2) is a functional receptor for the SARS CoV. 9 A transgenic mouse with human ACE-2 may be useful as an animal model of SARS. Furthermore, ACE-2 transgenic SCID mice should be useful as a human model for preclinical trial for SARS vaccines, for analyzing human immune responses against SARS infection in vivo. The effect of combination immunization with such SARS vaccines and nentralizing antibody-inducing DNA vaccines is now being studied

SARS study group. Coronavirus as a possible cause of severe acute

Identification of a novel coronavirus in patients with severe acute 3

The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene

Establishment and characterization of human

Generation of an immortal differentiated lung type-II

Effects of a SARS-associated coronavirus vaccine in monkeys

A DNA vaccine induces SARS coronavirus neutralization and

Angiotensin-converting enzyme 2 is a functional receptor for the SARS respiratory syndrome

The severe acute respiratory syndrome

using adenovirus vector

T hybrid cells secreting immunoregulatory molecules

epithelial cell line from the adult H-2K(b)tsA58 transgenic mouse

protective immunity in mice

This study was also supported by a Health T cells in rhesus monkeys. SARS S DNA vaccines elicit neutralizing antibody responses that generate protective immunity in a mouse model (8). However, its immunogenicity inhumans has yet to be established. Therefore, it is very important to evaluate the efficacy of SARS DNA vaccines in SCID-PBL/hu mice